Clinical Research Directory
Browse clinical research sites, groups, and studies.
New Markers of Glycation to Predict Gestational Diabetes Mellitus and Macrosomia.
Sponsor: University Hospital, Bordeaux
Summary
Gestational diabetes mellitus (GDM) increases the risk of macrosomia and other adverse pregnancy outcomes. Screening strategies are debated: universal vs. selective, and macrosomia may begin before the time of screening, suggesting that glycation markers may have an interest. The objective of this trail is to compare novel markers: skin autofluorescence and glycated albumin, to HbA1c (reference) as predictors of GDM, macrosomia and other adverse outcomes, in pregnant women.
Key Details
Gender
All
Age Range
18 Years - 99 Years
Study Type
INTERVENTIONAL
Enrollment
800
Start Date
2023-12-18
Completion Date
2028-09
Last Updated
2026-01-15
Healthy Volunteers
No
Interventions
Pregnant women
Gestational Diabetes Mellitus increases the risk of adverse pregnancy outcomes (such as macrosomia). The lack of early clinical symptoms leads to screen pregnant women for GDM, and the strategies of screening are a matter of debate. Interventions to control glucose levels in women with GDM have demonstrated efficacy in terms of macrosomia. However, macrosomia may start before the time of screening, suggesting that markers of glycation may have interest : skin autofluorescence, glycated albumin.
Locations (1)
Hopital Pellegrin
Bordeaux, France